Rentschler Biopharma marks construction milestone at new German buffer media facility
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
List view / Grid view
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
Efficacy research supports the widespread use of autonomous UVC disinfection for microbial surface decontamination, say AstraZeneca microbiology experts.
The pharma company invested $445m to expand its Coppell site.
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
The company will now put a total of $4.5 billion into the Virginia site, expanding its remit to include active pharmaceutical ingredients for cancer drugs.
Sets bioequivalence and active pharmaceutical ingredient (API) requirements for its new ANDA prioritisation programme.
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
7 October 2025 | By Rapid Micro Biosystems
This webinar showcases a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.
Pharma manufacturing facility construction placed at the heart of a policy announcement made on social media.
This whitepaper provides a detailed examination of Lonza’s holistic, data-driven approach to CCI, developed in collaboration with industry experts and applied across our global network for parenteral combination products.
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.